News & Videos - AMBU A/S [CBOE]

Pursuant to the Market Abuse Regulation, article 19, Ambu A/S hereby notifies receipt of information of the following transaction(s) made by persons discharging managerial responsibilities in Ambu A/S and/or their closely associated persons related to Ambu A/S’s shares admitted to trading and official listing on Nasdaq Copenhagen A/S. The attached document discloses the data of the transactions made in Ambu shares. Attachment 09_02_2024 Henrik Skak Bender...

Pursuant to Ambu A/S’ (Ambu) Remuneration Policy, a total of 172,956 Performance Share Units (PSUs) related to Ambu’s long-term incentive programme (LTIP) for 2023/24 have been granted on 6 February 2024 with retroactive effect from 1 January 2024. 49,109 of the PSUs have been granted to the Executive Management and 123,847 of the PSUs have been granted to other key employees. The LTIP covers the financial year 2023/24, and the final allocation of PSUs is conditional upon achievement of two...

In Q1 2023/24, Ambu delivered 14% organic revenue growth and a 10.0% EBIT margin before special items. This was driven by Endoscopy Solutions growing 25%, due to continued high double-digit growth within urology and ENT, combined with pulmonology growing 18%. “I am pleased with the performance within the first quarter of the year, showcasing our continued commitment to delivering strong profitable growth. With 25% growth in Endoscopy Solutions, an increased profitability level and a positive...

For the full 2022/23 financial year, Ambu reported 7.6% organic revenue growth. This was driven by Endoscope Solutions posting 15% organic growth, the main drivers being urology and ENT growing high double-digits, as well as pulmonology contributing positively, with a strengthened offering. As a result of Ambu’s focused execution, the company delivered an EBIT margin of 6.3%, mainly driven by revenue growth and reduced operational costs in distribution and staff, as well as a positive free...

Today, Ambu announces its financial guidance for the fiscal year 2023/24. Also, today, Ambu will publish its Q4 and full-year earnings release along with its Annual Report, including the company’s Sustainability Report, and its Remuneration Report and Corporate Governance Report for 2022/23. MARKET CONDITIONS During 2022/23, Ambu witnessed increased geopolitical uncertainty and a volatile macroenvironment, affecting the global economy and resulting in inflationary effects on raw materials,...

Thomas Frederik Schmidt will step down as CFO of Ambu by 31 December 2023; Henrik Skak Bender named as new CFO, effective 1 January 2024. Ambu A/S has appointed Henrik Skak Bender as the company’s new Chief Financial Officer and member of the Executive Management, effective 1 January 2024. Henrik succeeds Thomas Frederik Schmidt, who will step down, effective 31 December 2023. During Thomas’ period as CFO, the financial situation of Ambu has stabilised, the company has returned to positive...

Today, Ambu announces its preliminary financial 2022/23 results. For the financial year 2022/23, EBIT before special items totalled DKK 302m, with an EBIT margin before special items of 6.3% (previous outlook: 5 – 6%), mainly driven by scale in OPEX and product mix. PRELIMINARY FINANCIAL HIGHLIGHTS FOR THE FULL FINANCIAL YEAR 2022/23 Last year’s comparative figures are stated in brackets. Revenue was DKK 4,775m (DKK 4,444m), with organic growth of 7.6% (4%), driven by strong growth in...

This financial calendar lists the expected release dates of Ambu’s financial announcements for the financial year 2023/24, as well as the date of Ambu’s Annual General Meeting. 2023 8 NOVEMBER 2023 Annual Report 2022/23 13 DECEMBER 2023 Annual General Meeting 2023 2024 30 JANUARY 2024 Earnings release Q1 2023/24 14 MAY 2024 Earnings release Q2 2023/24 30 AUGUST 2024 Earnings release Q3 2023/24 30 SEPTEMBER 2024 End of fiscal year 2023/24 5 NOVEMBER 2024 Annual Report 2023/24 4 DECEMBER 2024...

In Q3 2022/23, Ambu delivered 8% organic revenue growth and a 7.6% EBIT margin. This was driven by Endoscopy Solutions growing 23%, due to high double-digit growth within urology and ENT, and pulmonology returning to positive growth year-over-year. Today, Ambu narrows its full-year 2022/23 organic revenue growth guidance to 6-8%, previously 5-8%, based on the company’s performance in Q3 and the first two months of Q4. On 10 July 2023, Ambu adjusted its financial guidance by upgrading its...

Pursuant to Ambu A/S’ (Ambu) Remuneration Policy, a total of 198,872 Performance Share Units (PSUs) related to Ambu’s long-term incentive programme (LTIP) for 2022/23 have been granted on 28 July 2023. 55,956 of the PSUs have been granted to the Executive Management and 142,916 of the PSUs have been granted to other key employees. The LTIP covers the financial year 2022/23, and the final allocation of PSUs will be within the range of 0-200% of the initial grant, subject to the actual...

Ambu raises its expectations for EBIT margin before special items to 5 - 6% (previously 3 - 5%) for the full-year 2022/23, based on its preliminary Q3 results. For Q3 2022/23, EBIT before special items totalled DKK 91m (DKK 42m), with an EBIT-margin before special items of 7.6% (3.7%), mainly driven by a better-than-expected gross margin, based on product mix and lower distribution costs. PRELIMINARY FINANCIAL HIGHLIGHTS FOR Q3 2022/23 Last year’s comparative figures are stated in brackets....

Ambu posts 4% organic revenue growth for the second quarter of 2022/23, in line with expectations. The quarter was driven by continued strong growth in urology and ENT, offset by pulmonology and Anaesthesia. Financial guidance is maintained for the fiscal year 2022/23, with organic revenue growth at 5-8% and EBIT margin before special items at 3-5%. “In the second quarter, Ambu delivers 4% organic revenue growth and 3.9% EBIT margin, in line with our expecta­tions. We delivered a slightly...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, CANADA, JAPAN, SOUTH AFRICA, HONG KONG OR AUSTRALIA, EXCEPT AS PERMITTED BY APPLICABLE LAW, OR IN ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION IS UNLAWFUL. THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND IS NOT AN OFFER OF SECURITIES IN ANY JURISDICTION. Ambu A/S (“Ambu” or the “Company”) has in connection with its accelerated bookbuild offering today...

Ambu A/S (“Ambu” of the “Company”) has completed its offering of new B shares and existing treasury B shares (together the “Shares”) through an accelerated bookbuilding process (the “Offering”). Further to company announcement no. 6 of 24 March 2023, Ambu has successfully completed an accelerated bookbuild offering of 11,577,957 new B shares and 250,000 existing treasury B shares (in aggregate corresponding to approximately 5.3% of Ambu’s issued B shares), at a sales price of...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, CANADA, JAPAN, SOUTH AFRICA, HONG KONG OR AUSTRALIA, EXCEPT AS PERMITTED BY APPLICABLE LAW, OR IN ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION IS UNLAWFUL. THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND IS NOT AN OFFER OF SECURITIES IN ANY JURISDICTION. Ambu A/S (“Ambu” or the “Company”) intends to raise approximately 5% of Ambu’s total B shares...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, CANADA, JAPAN, SOUTH AFRICA, HONG KONG OR AUSTRALIA, EXCEPT AS PERMITTED BY APPLICABLE LAW, OR IN ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION IS UNLAWFUL. THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND IS NOT AN OFFER OF SECURITIES IN ANY JURISDICTION. Ambu A/S (“Ambu” or the “Company”) intends to raise approximately 5% of Ambu’s total B shares...

Today, Ambu is hosting a Capital Markets Day. In this context, Ambu will outline its assessment of market potential and dynamics as it expands on its ZOOM IN strategy. This includes innovative solutions and execution, delivering sustainable profitable growth. Ambu maintains FY 2022/2023 financial guidance and specifies its long-term financial targets, which include 5-year organic revenue CAGR, EBIT margin as well as its planned reduction of financial leverage to its target NIBD/EBITDA ratio of...

Ambu invites institutional investors, analysts and financial media to the company’s Capital Markets Day on Tuesday 21 March 2023. On 21 March 2023, Ambu will host its Capital Markets Day for institutional investors, analysts and financial media, from 10:00-16:00 CET, at the headquarters of Ambu A/S, Baltorpbakken 13, 2750 Ballerup, Denmark. At the event, senior executives from Ambu and external speakers will join Chief Executive Officer, Britt Meelby Jensen, in sharing insights on the...

Ambu delivers solid performance for Q1 2022/23. The company posts 4% organic revenue growth for the quarter and continues to progress its new ZOOM IN strategy and global transform­ation program. Financial guidance maintained for the fiscal year 2022/23, with organic revenue growth at 5-8% and EBIT margin before special items at 3-5%. “In the first quarter of our fiscal year, we rolled out our ZOOM IN strategy across the organisation. The new strategy kicks off a transformation journey for...

Pursuant to the Market Abuse Regulation, article 19, Ambu A/S hereby notifies receipt of information of the following transaction(s) made by persons discharging managerial responsibilities in Ambu A/S and/or their closely associated persons related to Ambu A/S’s shares admitted to trading and official listing on Nasdaq Copenhagen A/S. The attached document discloses the data of the transactions made in Ambu shares. Attachment 29_11_2022 Thomas F Schmidt...